128 KRAS exon 2 wild-type patients were randomised to chemotherapy alone and 129 to chemotherapy with cetuximab between Feb 26 , 2007 , and Nov 1 , 2012.117 patients in the chemotherapy alone group and 119 in the chemotherapy plus cetuximab group were included in the primary analysis .